181 related articles for article (PubMed ID: 36430394)
1. GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF-κB/IκBα Pathways.
Scuderi SA; Filippone A; Basilotta R; Mannino D; Casili G; Capra AP; Chisari G; Colarossi L; Sava S; Campolo M; Esposito E; Paterniti I
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430394
[TBL] [Abstract][Full Text] [Related]
2. EZH2 and NF-κB: A context-dependent crosstalk and transcriptional regulation in cancer.
Kaur P; Verma S; Kushwaha PP; Gupta S
Cancer Lett; 2023 Apr; 560():216143. PubMed ID: 36958695
[TBL] [Abstract][Full Text] [Related]
3. Chronic Inflammation Pathway NF-κB Cooperates with Epigenetic Reprogramming to Drive the Malignant Progression of Glioblastoma.
Lin K; Gao W; Chen N; Yang S; Wang H; Wang R; Xie F; Meng J; Lam EW; Li S; Cheng W; Chen P; Wu H; Yan J; Jin D; Jin B
Int J Biol Sci; 2022; 18(15):5770-5786. PubMed ID: 36263173
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model of Subarachnoid Hemorrhage.
Luo Y; Fang Y; Kang R; Lenahan C; Gamdzyk M; Zhang Z; Okada T; Tang J; Chen S; Zhang JH
Stroke; 2020 Nov; 51(11):3320-3331. PubMed ID: 32933418
[TBL] [Abstract][Full Text] [Related]
5. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence.
Iannetti A; Ledoux AC; Tudhope SJ; Sellier H; Zhao B; Mowla S; Moore A; Hummerich H; Gewurz BE; Cockell SJ; Jat PS; Willmore E; Perkins ND
PLoS Genet; 2014 Sep; 10(9):e1004642. PubMed ID: 25255445
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.
Pereira ASA; Amaral MS; Vasconcelos EJR; Pires DS; Asif H; daSilva LF; Morales-Vicente DA; Carneiro VC; Angeli CB; Palmisano G; Fantappie MR; Pierce RJ; Setubal JC; Verjovski-Almeida S
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006873. PubMed ID: 30365505
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of IκBα in cardiomyocytes alleviates hydrogen peroxide-induced apoptosis and autophagy by inhibiting NF-κB activation.
Han M; Chen XC; Sun MH; Gai MT; Yang YN; Gao XM; Ma X; Chen BD; Ma YT
Lipids Health Dis; 2020 Jun; 19(1):150. PubMed ID: 32580730
[TBL] [Abstract][Full Text] [Related]
8. Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.
Tchoghandjian A; Jennewein C; Eckhardt I; Rajalingam K; Fulda S
Cell Death Dis; 2013 Mar; 4(3):e564. PubMed ID: 23538445
[TBL] [Abstract][Full Text] [Related]
9. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
10. GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells.
Xu H; Zhang L; Qian X; Zhou X; Yan Y; Zhou J; Ge W; Albahde M; Wang W
Exp Ther Med; 2019 Oct; 18(4):2608-2616. PubMed ID: 31572509
[TBL] [Abstract][Full Text] [Related]
11. GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.
Xiong X; Zhang J; Li A; Dai L; Qin S; Wang P; Liu W; Zhang Z; Li X; Liu Z
Cancer Biol Ther; 2020; 21(3):213-222. PubMed ID: 31651209
[TBL] [Abstract][Full Text] [Related]
12. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
[TBL] [Abstract][Full Text] [Related]
13. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.
Yu T; Wang Y; Hu Q; Wu W; Wu Y; Wei W; Han D; You Y; Lin N; Liu N
Oncotarget; 2017 Nov; 8(58):98348-98359. PubMed ID: 29228694
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic effect of enhancer of Zeste homolog 2 inhibitor GSK343 on periodontitis by regulating macrophage differentiation].
Zhongchao W; Liyuan F; Dan T; Cong Z; Shijun L
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):264-268. PubMed ID: 28675010
[TBL] [Abstract][Full Text] [Related]
15. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
16. SET domain containing 7 promotes oxygen-glucose deprivation/reoxygenation-induced PC12 cell inflammation and oxidative stress by regulating Keap1/Nrf2/ARE and NF-κB pathways.
Pan X; Fan J; Peng F; Xiao L; Yang Z
Bioengineered; 2022 Mar; 13(3):7253-7261. PubMed ID: 35259059
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57
Qiao E; Chen D; Li Q; Feng W; Yu X; Zhang X; Xia L; Jin J; Yang H
J Cell Biochem; 2019 Mar; 120(3):3978-3988. PubMed ID: 30378143
[TBL] [Abstract][Full Text] [Related]
18. EZH2 inhibitor GSK343 inhibits sepsis-induced intestinal disorders.
Yue D; Wang Z; Yang Y; Hu Z; Luo G; Wang F
Exp Ther Med; 2021 May; 21(5):437. PubMed ID: 33747174
[TBL] [Abstract][Full Text] [Related]
19. EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.
Bownes LV; Williams AP; Marayati R; Stafman LL; Markert H; Quinn CH; Wadhwani N; Aye JM; Stewart JE; Yoon KJ; Mroczek-Musulman E; Beierle EA
PLoS One; 2021; 16(3):e0246244. PubMed ID: 33690617
[TBL] [Abstract][Full Text] [Related]
20. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer.
Ren X; Chen C; Luo Y; Liu M; Li Y; Zheng S; Ye H; Fu Z; Li M; Li Z; Chen R
Mol Cancer; 2020 Feb; 19(1):35. PubMed ID: 32085715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
